Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.33 and traded as high as $3.86. Cumberland Pharmaceuticals shares last traded at $3.59, with a volume of 193,907 shares changing hands.

Analysts Set New Price Targets

Several research firms recently issued reports on CPIX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen raised Cumberland Pharmaceuticals to a “hold” rating in a report on Saturday, January 10th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cumberland Pharmaceuticals presently has an average rating of “Sell”.

Cumberland Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.11 and a current ratio of 1.23. The firm has a market cap of $53.71 million, a P/E ratio of -14.96 and a beta of -0.52. The company’s 50 day moving average is $3.78 and its 200 day moving average is $3.33.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 5.13% and a negative net margin of 8.06%.The company had revenue of $8.29 million for the quarter.

Institutional Trading of Cumberland Pharmaceuticals

A number of hedge funds have recently made changes to their positions in CPIX. Heron Bay Capital Management acquired a new position in shares of Cumberland Pharmaceuticals in the second quarter valued at approximately $111,000. XTX Topco Ltd bought a new stake in Cumberland Pharmaceuticals during the 2nd quarter worth approximately $34,000. Bridgeway Capital Management LLC grew its holdings in Cumberland Pharmaceuticals by 2.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after acquiring an additional 4,200 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Cumberland Pharmaceuticals by 11.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock valued at $876,000 after acquiring an additional 27,980 shares during the period. Finally, Two Sigma Investments LP raised its stake in shares of Cumberland Pharmaceuticals by 16.5% during the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after acquiring an additional 5,326 shares during the last quarter. 15.51% of the stock is owned by institutional investors and hedge funds.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.